KY SB77

Establishes the Ibogaine Research and Intellectual Property Fund in the State Treasury, administered by the Department of Agriculture, to fund public-private partnerships for clinical trials studying ibogaine as a treatment for opioid use disorder, substance use disorders, and other neurological or mental health conditions.

Transfers $21 million per fiscal year from the opioid abatement trust fund during the 2026-2028 biennium ($42 million total) to fund the ibogaine research program.

Requires drug developers to match the Commonwealth's investment with equal funding, use exclusively in-state clinicians, facilities, and study participants, and pursue FDA breakthrough therapy designation for ibogaine.

Mandates quarterly progress and financial reports from drug developers, with annual reports to the Legislative Research Commission's Interim Joint Committee on Health Services.

Grants Kentucky a proportional share of intellectual property proceeds from multistate clinical trials, with future revenues directed toward programs benefiting populations with opioid use disorder, PTSD, traumatic brain injury, and other treatable conditions.